PepGen Inc. (PEPG) is a Boston-based, clinical-stage biotechnology company developing oligonucleotide therapies for severe neuromuscular and neurological diseases. Its lead candidate, PGN-EDODM1, targets myotonic dystrophy type 1 (DM1), a progressive genetic disorder with no approved therapy addressing its underlying cause. The company has no product revenue and funds operations from its balance sheet.
Shares recently changed hands at $4.12, up 7.57%, or $0.29, from the prior session's close of $3.83. The direction is firmly positive, though the advance recovers only part of the ground lost since mid-November. No verified news catalyst was identified for the session; the move is consistent with a technical rebound after the stock fell roughly 27% from its November 11 close of $5.26 to Wednesday's $3.83.
No verified news or fundamental catalyst found explains Thursday's advance. There was no new press release, no updated clinical readout, no disclosed regulatory change, and no fresh analyst revision published ahead of the move. The stock's own recent history offers the more plausible explanation.
The rally that peaked on November 10 and 11 was triggered by genuine, material news: 10 mg/kg Phase 2 FREEDOM2-DM1 results showing 46.5% mean splicing correction in muscle tissue versus 6.8% for placebo, with improvements in myotonia, grip strength and mobility. That session produced a 92.89% gain on roughly 44.5 million shares. Management then moved quickly to capitalize, launching and pricing a $125 million public offering of 25 million shares at $5.00, with net proceeds of about $116.9 million.
That sequence created two pressures: profit-taking after a one-day doubling, and a new block of stock sold at $5.00 that now sits above the market. With only about 36.1 million shares in the float and a beta above 2, the stock is prone to outsized swings on modest order flow. Thursday's gain is most consistent with a partial retracement of that decline as sellers exhausted and short-term buyers returned, rather than the arrival of new information.
Turnover has cooled materially. After the 44.5 million-share session on November 10, volume stepped down through the following week to roughly 1.3 million to 3 million shares per session, and current activity is running below that post-data peak — the signature of a stock moving on residual positioning rather than institutional accumulation.
The move is not a sector-wide event. Large-cap biotechnology and broad equity indices showed no comparable gain, and the advance diverges from the flat-to-lower tape seen across most clinical-stage peers. The one relevant comparator, DYN, is approaching its own pivotal DM1 trial, and competitive readouts remain the key swing factor for sentiment across the indication.
Technically, the stock is holding above its 50-day and 200-day moving averages near $2.85 and $2.91, having broken decisively above both in the November 10 gap. The $4.21 high reached on Wednesday is the nearest resistance; $3.73, Wednesday's low, is the first level of support, with the $5.00 offering price acting as a psychological ceiling. Market capitalization is roughly $285 million.
A score of 0 would mean no meaningful news and a move that is routine for the stock; 100 would mean transformative news and an extreme, rare price move. This session scores 17 out of 100.
The verified news backdrop is strong in substance — the FREEDOM2-DM1 efficacy data reshaped the investment case for a company of this size — but nothing new was published for this session, so news strength was minimal relative to the move. The price move itself was unremarkable by the stock's own standards: 7.57% is about 1.4 times the typical daily swing of roughly 5.6%, and eight of the last 60 sessions produced equal or larger absolute moves.
The near-term calendar is dominated by clinical execution. Interim 10 mg/kg safety and 5 mg/kg clinical data from the FREEDOM-OLE extension study are expected in January 2027, followed by results from the fully enrolled 12.5 mg/kg cohort in the first half of 2027. Those datasets are intended to support an end-of-Phase 2 meeting with U.S. regulators in the second half of 2027, contingent on lifting the partial clinical hold that currently restricts U.S. enrollment.
Financial flexibility is the other variable. PepGen ended the third quarter with $104.8 million in cash and securities and has said that, together with offering proceeds, funding extends into 2028, though further capital raises remain possible. The company posted a $19.4 million net loss in the quarter and missed consensus EPS by a penny. Analyst sentiment has improved sharply, with a median target near $11 and a Buy-leaning consensus, but ratings now hinge on sustained functional benefit, chronic safety data, and the registrational path rather than on a single readout. Key risks include competitive DM1 data, a thin float that amplifies volatility, and continued dilution risk.
Tickeron's Trending AI Robots page curates the strongest-performing automated strategies from a library of hundreds of AI trading bots covering thousands of tickers. The section highlights only those bots posting the best results under present market conditions, and the roster spans a wide range of approaches — differing by strategy logic, holding period, performance metrics, and the specific symbols each bot trades. For investors looking to see how systematic strategies are positioned right now, it is a useful starting point to review the current leaders and compare their track records.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where PEPG declined for three days, in 256 of 284 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
The 10-day RSI Indicator for PEPG moved out of overbought territory on November 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 24 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
PEPG broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 59 cases where PEPG's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on PEPG as a result. In 74 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for PEPG just turned positive on November 10, 2026. Looking at past instances where PEPG's MACD turned positive, the stock continued to rise in 34 of 39 cases over the following month. The odds of a continued upward trend are 87%.
PEPG moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PEPG crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Following a +120.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where PEPG advanced for three days, in 199 of 230 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The Aroon Indicator entered an Uptrend today. In 104 of 112 cases where PEPG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.431) is normal, around the industry mean (3.592). P/E Ratio (-2.470) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. PEPG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PEPG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology